In the latest episode of the Blackstone Podcast, Nick Galakatos, Head of Blackstone Life Sciences, highlights the growing demand for capital across the life sciences industry, and how BXLS is helping bring vital but underfunded medicines and technologies to market. Nick also shares his background as a scientist and an investor, and discusses the therapeutic and disease areas that hold the most promise for meaningful impact.
* * * * *
Neither this podcast, nor any of the information contained herein or therein constitutes an offer to sell, or a solicitation of an offer to buy, any security or instrument in or to participate in any trading strategy with any Blackstone fund or other investment vehicle.
Past performance is not indicative of future results and there is no assurance that any Blackstone fund will achieve its objectives or avoid significant losses. This blog post and the podcast may contain forward-looking statements; such statements are subject to various risks and uncertainties.
For information about Blackstone's business, including risks and financial information, please refer to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. For additional information, see Blackstone’s public filings at ir.blackstone.com.